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Alzheimer’s disease (AD) etiological studies suggest that an elevation in amyloid-β peptides (Aβ) level contributes to aggregations
of the peptide and subsequent development of the disease. The major constituent of these amyloid peptides is the 1 to 40–42
residue peptide (Aβ40−42) derived from amyloid protein precursor (APP). Most likely, reducing Aβ levels in the brain may block
both its aggregation and neurotoxicity and would be beneﬁcial for patients with AD. Among the several possible ways to lower
Aβ accumulation in the cells, we have selectively chosen to target the primary step in the Aβ cascade, namely, to reduce APP gene
expression. Toward this end, we engineered speciﬁc SOFA-HDV ribozymes, a new generation of catalytic RNA tools, to decrease
APP mRNA levels. Additionally, we demonstrated that APP-ribozymes are eﬀective at decreasing APP mRNA and protein levels as
well as Aβ levels in neuronal cells. Our results could lay the groundwork for a new protective treatment for AD.
1.Introduction
Alzheimer’s disease (AD) is a degenerative disorder of the
human central nervous system (CNS). Its clinical and neu-
ropathological features are deﬁned by a progressive loss
of cognitive function and by the onset of a slowly pro-
gressive impairment of memory during mid- to late-adult
life. The neuropathological hallmarks of AD include the
accumulation and aggregation of amyloid-β peptide (Aβ),
neuroﬁbrillary tangles, astrocytic gliosis, and reductions
in the numbers of both neurons and synapses in many
areas of the brain, particularly in the cerebral cortex and
hippocampus [1]. Strong evidence from multiple studies
suggests that defects in Aβ regulation are one of the central
biochemical events leading to the development of AD [2].
The neurotoxic Aβ fragment originates from the amyloid
protein precursor (APP) following sequential cleavages by β
(BACE) and γ-secretases (presenilin complex). Observations
on the physiological processing of APP and on the eﬀects of
pathogenic mutations in the APP and/or the presenilin genes
have led to the hypothesis that aberrant processing of APP
into Aβ peptides is linked to AD [3]. We have previously
reported strong evidence indicating that the amyloid cascade
is an early and critical event in the neurodegeneration
associated with AD. For example, cell lines and/or transgenic
mice expressing mutant presenilin 1 (PS1), presenilin 2
(PS2), or APP exhibit an accelerated rate of neurotoxic Aβ
formation [4]. Thus, the three known genetic causes of
familial AD aﬀect Aβ metabolism. Moreover, the ε4a l l e l e
of apolipoprotein E, a strong genetic risk factor for the
development of AD, has been linked to either enhancing
Aβ aggregation or decreasing its clearance in brain tissue
[5, 6]. Altogether, these observations strongly suggest that
targetingAβ metabolismisaworthwhiletherapeuticapproach
and that reducing its level in the brain may block both
the neurodegenerative process and cognitive decline. Most
likely, an approach that reduces either the level of Aβ or the
rate of its aggregation and deposition in the brain would2 International Journal of Alzheimer’s Disease
be beneﬁcial for patients with AD. Targeting the secretases
may be risky because they appear to have multiple roles in
cells. We have decided to address the problem with a new
generation of ribozymes (Rz) targeting the ﬁrst step in the
amyloid cascade, speciﬁcally, the APP mRNA.
Hepatitis Delta Virus ribozyme (HDV Rz) is an interest-
ing potential tool for the development of a gene-inactivation
system because it is well adapted to the human cell envi-
ronment [7]. In fact, this ribozyme oﬀers several unique
properties, including the natural ability to function in the
presence of human proteins and at physiological magnesium
concentrations as well as outstanding molecular stability
(i.e., it has a long half-life) [8]. Recently, a novel target-
dependent ribozyme that increases HDV Rz ﬁdelity was
engineered [9]. This new ribozyme possesses a module
(the SOFA, for Speciﬁc On/Oﬀ Adaptor) that switches the
cleavage activity from Oﬀ to On when in the presence of
theappropriatesubstrate(Figure 1).Speciﬁcally,thismodule
is composed of three domains: a blocker, a biosensor, and a
stabilizer. The blocker sequence inhibits the cleavage activity
of the ribozyme by intramolecularly binding the recognition
domain of the Rz, which was limited to only 7 nucleotides
before the addition of the module. Binding of the blocker
switches the ribozyme domain to an inactive state, namely,
the Oﬀ conformation. Upon addition of the substrate,
the biosensor binds its complementary sequence on the
substrate and unlocks the SOFA module, thereby permitting
a switch of the ribozyme into the active fold, namely, the
On conformation. The sequences of the substrate binding of
both the ribozyme recognition and biosensor domains are
not contiguous, but rather are separated by a small region
called the spacer that varies from 4 to 7 nucleotides for
optimaldesign[10].Finally,thepresenceofastem(namely,a
stabilizer) that brings together both the 5  and 3  extremities
has no eﬀect on the cleavage activity but stabilizes the SOFA-
HDV Rz in vivo against ribonucleases. A proof of concept
of this man-made ribozyme has been demonstrated both
in vitro and in vivo using ribozymes that cleaved various
mRNA and viral RNA [11–13]. The fact that the SOFA-HDV
Rz is activated by its mRNA substrate greatly diminishes
its nonspeciﬁc eﬀects; consequently, it displays signiﬁcant
potential for applications in both functional genomics and
gene therapy.
Inthisstudy,weevaluatedthepotentialofthenewSOFA-
HDV ribozymes as an RNA silencing tool in mammalian
cells. In cell culture, we demonstrated the eﬀects of SOFA-
HDV Rz targeting APP mRNA on Aβ production.
2.ExperimentalProcedures
2.1. SOFA-HDV Ribozyme DNA Constructs. SOFA-HDV
ribozymes were constructed using a PCR-based strategy
that included two complementary and overlapping oligonu-
cleotides. Brieﬂy, two DNA oligonucleotides were synthe-
sized and annealed with the reverse primer (5 -CCAGCT-
AGAAAGGGTCCCTTAGCCATCCGCGAACGGATGC-
CCA(N)6(P1)ACCGCGAGGAGGTGGACCCTG(N)4(BL))and
the sense primer (5 -TTAATACGACTCACTATAGGGCC-
AGCTAGTTT(N)12(BS)(N)4(BL)CAGGGTCCACC), where N
isA,C,G,orT,andP1,BS,andBLindicatetheP1,biosensor,
and blocker sequences, respectively. It is important to note
that both the P1 and BS segments were varied to correspond
to speciﬁc APP mRNA sequences and that the BL was
complementary to the ﬁrst 4 nucleotides on the 5  end of
the Rz’s recognition domain. For in vitro synthesis of the
ribozymes, the sense primer also included the sequence of
the T7 RNA polymerase promoter at the 5  end. The ﬁlling
reaction was performed in a 100-μL volume containing
20mM Tris-HCl (pH 8.8), 10mM KCl, 10mM (NH4)2SO4,
2mMMgSO 4, 0.1% Triton X-100, 2μMo fe a c hd N T P ,1μM
of each DNA oligo, and 5U of Pwo DNA polymerase (Roche
Diagnostics). The reactions were ethanol precipitated and
washed and the DNA pellets resuspended in 56μLo f
deionized water. The resulting PCR products were directly
used for in vitro transcription reactions (see below). For
the in cellulo experiments, the PCR products were inserted
into the EcoRV site of pCDNA3 (Invitrogen). The SOFA-
HDV-Rz cassettes were removed by digestion with BamHI
and subcloned into pRNAT-U6.1/lentivector (GenScript)
under control of the U6 snRNA promoter. The resulting
plasmids were named pRNAT-SOFA-HDV-Rz-APPX, where
X represents the APP cleavage position.
2.2. In Vitro Transcription of SOFA-HDV Rz and APP
mRNA. RNA transcriptions were performed as previously
described [14]. In the case of the SOFA-HDV ribozymes,
the resuspended DNA pellets were used in 100-μL transcrip-
tion reactions containing 80mM HEPES-KOH (pH 7.5),
24mM MgCl2, 2mM spermidine, 40mM DTT, 5mM of
each rNTP, 0.01U of pyrophosphatase (Roche Diagnostics),
24U of RNAGuard (Amersham Biosciences), and 10μgo f
puriﬁed T7 RNA polymerase and allowed to proceed for
4h at 37 ◦C. The reactions were then treated with 4U
of RQ1 DNase (Promega), phenol-chloroform extracted,
ethanol precipitated, and washed. Following these steps, the
RNA pellets were resuspended in 40μL of deionized water.
One volume of loading buﬀer (97.5% formamide, 0.05%
bromophenol blue, 0.05% xylene cyanol, 10mM EDTA) was
added, and the samples were fractionated by 8% denaturing
(8M urea) polyacrylamide gel electrophoresis (PAGE, 19:1
ratio of acrylamide to bisacrylamide), using 45mM Tris-
borate (pH 7.5) and 1mM EDTA. The RNA bands were
visualized by UV shadowing, and the gel slices were cut
out and eluted overnight using 500mM ammonium acetate,
1mM EDTA, and 0.1% SDS. After ethanol precipitation,
the RNA transcripts were resuspended in deionized water
and quantiﬁed by UV absorbance at 260nm. The plasmid
pAPP12 (containing a full-length copy of the APP mRNA)
was used as a template. After linearization by the StuI
restriction enzyme, mRNA was synthesized as described
above and puriﬁed using 5% PAGE. After puriﬁcation,
the transcripts (40pmol) were dephosphorylated in a ﬁnal
volume of 50μL containing 200mM Tris-HCl (pH 8.0), 10U
RNAGuard, and 0.2U of calf intestinal alkaline phosphatase
(Amersham BioSciences) at 37◦C for 30min. The reactions
were puriﬁed by extracting twice with phenol:chloroform,
and the mRNA was then precipitated with ethanol, washed
with 70% ethanol, and dried. Dephosphorylated RNAInternational Journal of Alzheimer’s Disease 3
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Figure 1: Secondary structure of both the Oﬀ and On conformations of the SOFA-HDV ribozyme. The original HDV ribozymes in the
grey shaded boxes with its recognition domain (in blue) indicated. The SOFA is composed of three motifs: the biosensor (in green), blocker
(in red), and stabilizer stem. Upon the addition of APP mRNA, sequence-speciﬁc hybridization to the ribozyme occurs, and the substrate is
subsequently cleaved.
(∼6pmol) was 5  -end-labeled in a ﬁnal volume of 10μL
containing 3.2pmol of [γ-32P]ATP (6000Ci/mmol, New
England Nuclear), 10mM Tris-HCl (pH 7.5), 10mM MgCl2,
50mM KCl, and 3 U of T4 polynucleotide kinase (United
States Biochemicals) at 37◦C for 90min. The reaction was
stopped by the addition of formamide dye buﬀer (5μL), and
the reaction mixtures were fractionated through denaturing
5% PAGE gels and recovered as described above.
2.3. Ribonuclease H Probing and Primer Extension Assays.
Ribonuclease H (RNase H) reactions were performed with
a library of randomized oligonucleotides (5 -N6CD-3 ,
where N is for any A, C, G, or T residue and D is
for any A, T, or G residue). Speciﬁcally, nonradioactive
APP mRNA (0.5μM) and randomized oligonucleotides
(5μM) were preincubated for 10min at 25◦Ci naﬁ n a l
volume of 8μL containing 20mM Tris-HCl (pH 7.5),
20mM KCl, 10mM MgCl2,0 . 1 m ME D T A ,a n d0 . 1 m M
DTT. RNase H (0.5 U, United States Biochemicals) was
then added, and the samples were incubated at 37◦Cf o r
30min. After the incubation, 90μL of water was added,
and the mixture was phenol:chloroform extracted. The
nucleic acids were then precipitated with ethanol, washed,
and dried. Four DNA oligonucleotides complementary
to the APP RNA were purchased from Invitrogen (5 -
GTTCCTCAGCCTCTTCCT-3  (position 928-911), 5 -TCA-
GCCAGTGGGCAACAC-3  (position 719-702), 5 -GTC-
AGGAACGAGAAGGGC-3 (position 540-523),and5 -CTG-
AATCCCACTTCCCAT-3  (position310-293)).Theoligonu-
cleotides (10pmol) were 5 -end-labeled as described above.
The 32P-end-labeled oligonucleotides were puriﬁed with
denaturing 20% PAGE, and the relevant bands were excised
from the gel and eluted overnight at 25◦C, passed through
a G-25 spun column, ethanol precipitated, washed, dried,
and dissolved in deionized water (60μL). 5 -32P-labeled
primer (6μL) and 10X reverse transcriptase buﬀer (0.6μL
of 500mM Tris-HCl (pH 8.3), 800mM KCl, and 100mM
MgCl2) were used to resuspend the pellets resulting from
the RNase H hydrolysis. The primer annealing step was
performed by successively incubating the samples at 65◦C
f o r2 m i nf o l l o w e db y2 m i no ni c e .T h er e a c t i o n sw e r e
initiated by adding 0.8mM of each dNTP, 3.3mM DTT, and
100U of Superscript II Reverse transcriptase (Invitrogen) in
aﬁ n a lv o l u m eo f1 2μL. The samples were incubated at 45◦C
for 30min and then ethanol precipitated and analyzed by
5% sequencing PAGE. DNA sequencing reactions using the
same primer were migrated on the same gels to allow for
identiﬁcation of the primer extension stops. The results were
visualized with a PhosphorImager.4 International Journal of Alzheimer’s Disease
2.4. Ribozyme Cleavage In Vitro. Cleavage reactions were
carried out under single turnover conditions ([Rz]   [S]),
as previously described [15]. Speciﬁcally, 32P-end-labeled
APP mRNA (50nM) was mixed with SOFA-HDV ribozymes
(1μM) in a 10-μL mixture containing 50mM Tris-HCl (pH
7.5) and 10mM MgCl2 and then incubated at 37◦Cf o r1h .
The reactions were stopped by the addition of loading buﬀer,
RNA fractionated with denaturing 5% PAGE, and analyzed
with a PhosphorImager.
2.5. Cell Culture and Transfection. A subclone of the human
embryonic kidney cell line HEK-293 (tsA-201 cells, which
were kindly provided by Dr. Mohamed Chahine, Laval Uni-
versity) and human neuroblastoma SH-SY5Y cells (ATCC)
were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM, Gibco) supplemented with 10% (v/v) fetal bovine
serum (Biomedia). Stock cultures were maintained at 37◦C
in a humidiﬁed atmosphere with 5% CO2. The HEK-293
cells were transiently transfected with pRNAT-SOFA-HDV-
Rz-APPX (Rz-APP-X) plasmid using the calcium phosphate
procedure. The empty pRNAT-U6.1 vector (GenScript) was
used as a control. The SH-SY5Y cells were transduced using
a lentiviral system. This system consists of the multiply
deleted packaging construct pCMVΔR8.91 (which encodes
Gag, Pol, Tat, and Rev), the pMD.G expressing vesicular
stomatitis virus (VSV-G) surface glycoprotein (G), and
pRNAT-U6 (either with or without Rz-APPX). To produce
the infectious virions, HEK-293 cells (2 × 106) were plated
on 5 dishes (10cm) and transfected the next day with 20μg
of Rz-APPX, 15μg pCMVΔR8.91, and 5μg pMDG using
the calcium phosphate procedure. Conditioned medium
was harvested at 48hr after transfection, cleared of debris
by low-speed centrifugation, and ﬁltered through 0.45μm
ﬁlters (Sarstedt). The ﬁltrate containing the virions was
concentrated by ultracentrifugation at 71,000 × gf o r9 0
minutes at 16◦C using a SW-40 Beckman rotor, followed
by a second cycle of centrifugation for the collected and
resuspended pellets at 84,000 × g for 90min (using a 4-
mL centrifuge tube; SW60 Beckman rotor). Virions pellets
were then resuspended in 0.5mL of phosphate buﬀered
saline (PBS). SHSY-5Y cells were infected with 0.2mL of the
virions expressing SOFA-HDV-Rz-APPX in the presence of
6μg/mL polybrene (hexadimethrine bromide, Sigma). Three
days postinfection, the medium was replaced with medium
containing 600μg/mL G418 for selection. The transduced
cells were maintained as a stable population. The culture
medium was changed every 3-4 days for the duration of the
experiment.
2.6. SOFA-HDV Ribozyme Expression. To test the expression
of the Rz-APPX, total RNA was extracted from trans-
duced cells using the TRIzol reagent according to the
manufacturer’s recommendations (Invitrogen). Total RNA
extracts were then used in primer extension experiments for
ribozyme detection. Brieﬂy, the primers, corresponding to
the 3  complementary sequence of either SOFA-HDV-RzX
(5 -GGGTCCCTTAGCCATGCGCGAACG-3 )o rU 6R N A
(5 -GGCCATGCTAATCTTCTCTG-3 ), were 5 -end-labeled
with [γ-32P]ATP (6000Ci/mmol; New England Nuclear), as
previously published [13], annealed to 10μgo ft o t a lR N A
by a 5min incubation at 65◦C and immediately chilled
on ice. The reactions were initiated with the addition of
0.4mM of dNTPs, 10mM DTT, and 200 units of Superscript
II reverse transcriptase (Invitrogen) in a buﬀer containing
50mM Tris-HCl (pH 8.3), 75mM KCl, and 3mM MgCl2
in a ﬁnal volume of 50μL. The samples were incubated at
42◦C for 50min; the reactions were stopped by heating the
samples to 70◦C for 15min and then fractionated through
10% denaturing polyacrylamide gel electrophoresis.
2.7. Real-Time RT-PCR. First-strand cDNA synthesis was
performed using 2μg of total RNA in the presence of poly dT
primers and 200 units of SuperScript II reverse transcriptase.
Aliquots of 2μL from the resulting single-stranded cDNA
products were used along with the appropriate primers
(see below) for APP and GAPDH. Ampliﬁcations were
performed for each sample from each separate well in a
total volume of 25μL containing 1X SYBR Green Universal
PCR Master Mix and 400nM of speciﬁc forward and
reverse primers. The primers were designed to overlap the
boundaries of two exons (to avoid ampliﬁcation of genomic
DNA), using the Primer Express software v2.0 (Applied
Biosystems). Speciﬁcally, two pairs of primers were designed
to amplify the APP mRNA. The ﬁrst pair (sense primer
5 -GGCGGTGTTGTCATAGCGA-3  and antisense primer
5 -TGCATCTTGGACAGGTGGC-3 ) provided an amplicon
of 136 base pairs (bp), whereas the second pair (sense
primers 5 -AACGAAGTTGAGCCTGTTGATG-3  and anti-
sense primer 5 -AACGAAGGCTGGCACAAC-3 ) ampliﬁed
a 67-bp fragment. Ampliﬁcation of GAPDH mRNA using
the sense primer 5 -CGACACTTCCAGCTCTTTGCT-3  and
antisense primer 5 -GAATCAGGGTTATCTGGTCATCG-3 ,
which produces an amplicon of 131bp, was also per-
formed. The PCR ampliﬁcations were performed on an ABI
Prism 7000 Sequence Detector System (Applied Biosystems),
according to the manufacturer’s instructions and using the
following conditions: 1 cycle at 95◦C for 10min, followed by
40 cycles at 95◦C for 15s, 58◦C for 10s, 72◦Cf o r2 0s ,a n da
ﬁnalstepat60◦Cfor60s.Thecontrolsampleswereampliﬁed
without the reverse transcription step.
2.8. Preparation of Cell Lysates. Native and transfected cells
were rinsed twice with ice-cold PBS and then lysed for
3 0m i no ni c ei nc e l ll y s i sb u ﬀer containing 50mM Tris (pH
7.6), 150mM NaCl, 2mM EDTA, 1% NP-40, 20mM PMSF,
and minicomplete protease inhibitors (Roche-Diagnostic).
Insoluble material was removed by centrifugation at 13,000
× gf o r1 5m i na t4 ◦C. Finally, the proteins were quantiﬁed
using a standard Bradford assay (Bio-Rad).
2.9. Western Blot Analysis of APP Processing. Western blot
analysis was performed as previously described [16]. Brieﬂy,
20μg of total protein from each sample was mixed with
N o v e x2 Xr e d u c i n gs a m p l eb u ﬀer containing 500mM Tris-
HCl (pH 6.8), 20% glycerol, 10% SDS, 0.1% bromophenol
blue, and 5%β-mercaptoethanol. The samples were then
boiled for 5min and subjected to SDS-PAGE. Following
the migration, proteins were transferred onto a PVDFInternational Journal of Alzheimer’s Disease 5
APP mRNA
RNase H 
Primer
extension
Rz  cleavage 
Selection of potential 
SOFA-HDV-Rz-APPx  
Primers
Hybridization
position
928
719
540
293
5
5
5
5
5
3
3
3
3
3
911
702
523
310
5 NNNNNNCD-3
R
z
-
H
B
V
R
z
-
A
P
P
2
7
6
R
z
-
A
P
P
4
4
0
R
z
-
A
P
P
4
4
4
R
z
-
A
P
P
4
4
6
R
z
-
A
P
P
4
5
9
R
z
-
A
P
P
4
6
5
R
z
-
A
P
P
7
5
3
R
z
-
A
P
P
7
5
6
R
z
-
A
P
P
7
8
4
R
z
-
A
P
P
8
8
5
−
Figure 2: Selection of APP-SOFA-HDV ribozyme with the greatest potential cleavage. The left portion illustrates the strategy that was used
to identify potential cleavage sites. APP mRNA was preincubated in the presence of a 7nt long randomized DNA oligonucleotide, and
RNA/DNA heteroduplexes were hydrolyzed by RNase H. Accessible regions were then visualized by primer extension using one of the four
5 -end-labeled primers (in box) complementary to sequences retrieved in the ﬁrst ∼900 nucleotides of the APP mRNA. Once the most
accessible sites were identiﬁed, the appropriate SOFA-HDV ribozymes were synthesized and the cleavage activity was tested in vitro using
5 -end-labeled APP mRNA. A typical autoradiogram of a resulting PAGE is indicated in the right panel. The number of each Rz indicates the
cleavage position within the APP mRNA. The Rz-HBV, previously used for HBV RNA cleavage [15], served as an irrelevant Rz. “-” indicates
a reaction without Rz.
membrane (Millipore) according to the manufacturer’s pro-
tocol. The membranes were probed with an anti-APP C-
terminal antibody (A8717, Sigma-Aldrich) and β-tubulin
speciﬁc antibody (antibody E7 for β-tubulin, Developmental
Studies Hybridoma Bank). The blots were revealed using a
chemiluminescence detection system (Immobilon Western,
Millipore) according to the manufacturer’s recommenda-
tions. The intensity of the signals was analyzed using image
densitometry software (Imaging Densitometry, Bio-Rad).
The level of β-tubulin was used to normalize the levels of
APP (i.e., the ratio of APP versus β-tubulin) to control
for diﬀerences in the loading of total proteins. Modulations
of the APP levels in the cells treated with Rz-APP-X were
expressed as a percentage of the level in the control cells
(empty vector).
2.10. Quantitation of Aβ Using the Sandwich ELISA Method.
Following SH-SY5Y transduction and during the selection,
media was collected, preserved, and frozen at −80◦C.
Following, secreted Aβ was measured by sandwich ELISA,
according the manufacturer’s protocol (Human Amyloid β
(Aβ 1-x) Assay Kit, IBL).
2.11. Statistical Analysis. For the in vitro data, the results
from several experiments were analyzed using Student’s t-
test. Diﬀerences were considered signiﬁcant at P<0.05.
3. Results
3.1. Design and Selection of APP-Speciﬁc SOFA-HDV Ribo-
zymes. The ﬁrst step of this study consisted of designing
a collection of ribozymes that produced in vitro cleavage
of the APP mRNA. Due to unfavorable competition with
intramolecular base pairing, the target sequences located in
single-stranded regions of an mRNA are potentially more
accessible for Rz binding than those in double-stranded
regions. It has been demonstrated that both target site
accessibility and the ability to form an active ribozyme-
substrate complex constitute interdependent factors that
can be addressed using a combinatorial library of oligonu-
cleotides or ribozymes [17]. To identify the cleavage sites
with the greatest potential for targeting, we adopted a pro-
cedure based on the use of a library of partially randomized
oligonucleotides mimicking the interaction with the recog-
nition domain of the target [15]( Figure 2). In principle,
all of the accessible sites within the APP mRNA should be
speciﬁcally bound by an oligonucleotide and the resulting
RNA-DNA heteroduplex subsequently hydrolyzed by RNase
H. The resulting cleavage sites were identiﬁed by primer
extension reactions using 5 -end-labeled primers, and the
most potent SOFA-HDV ribozymes were tested for cleavage
activity. The library was composed of oligonucleotides that
were 8 nucleotides in length corresponding to one residue
before the cleavage site (i.e., position -1), which had to be
single stranded for cleavage to occur, and the 7 residues of
the recognition domain of the ribozyme. It is important
to note that this experiment considered only the binding
domain of the ribozyme and not the SOFA module. It
would be irrelevant to perform RNase H assays using long
oligonucleotides that included the complementary sequence
of the ribozyme’s recognition domain, spacer and biosensor
sequences. In that case, the spacer would also be bound,
leading to signiﬁcant formation of the duplexes and the
introduction of an important bias. The library was designed6 International Journal of Alzheimer’s Disease
Table 1: Determination of the most potential cleavage sites within APP mRNA.
Cleavage position mRNA sequence1
recognition domain/biosensor domain Accessibility2 SOFA-HDv Rz cleavage activity (%)3
276 5 -GCACAUG/CCAGAAUGGGAA-3  ++ 62
440 5 -GCAAGCG/GCAAGCAGUGCA-3  +++ 18
444 5 -GCGGGGC/GCAGUGCAAGAC-3  +++ 20
446 5 -GGGGCCG/AGUGCAAGACCC-3  +++ 26
459 5 -GUGCAAG/UCCCCACUUUGU-3  +++ 14
465 5 -GACCCAU/CUUUGUGAUUCC-3  ++ 26
753 5 -GGAGGAU/GGAUGUCUGGUG-3  ++ 36
756 5 -GGAUGAC/UGUCUGGUGGGG-3  +3 6
784 5 -GCAGACA/UAUGCAGAUGGG-3  +2 5
885 5 -GGACGAU/UGGUGAUGAGGU-3  +7 1
1The sequences of the mRNA bound by both the ribozyme’ recognition and biosensor domains. 2 Accessibility of potential cleavage sites based on RNase H
hydrolysis. 3 Percentage of cleavage activity of the various SOFA-HDV ribozymes targeting the APP mRNA.
while taking into consideration the sequence speciﬁcities of
the HDV ribozyme. Speciﬁcally, the nucleotide in position
1 cannot be a guanosine; therefore, the 3  end residue of
the oligonucleotide cannot be a cytosine. Moreover, the ﬁrst
base between the ribozyme’s recognition domain and the
target must be a GU wobble base pair. Consequently, the
oligonucleotide included a cytosine at the corresponding
position. This constraint led to a library of 12,288 diﬀerent
variants corresponding to the 5 -N6CD-3 . The action of
a ribozyme within the 5 -end of an mRNA region should
enhance the probability that the cleavage product results in
an RNA that cannot encode an active protein. Because each
primer produced a readable sequence of 200 to 300 bases,
4d i ﬀerent oligonucleotides were designed for the reverse
transcriptase reaction to analyze the ﬁrst ∼900 nucleotides
of the APP transcripts corresponding to the 1040 nucleotides
of the 5  end (see Section 2). The relative level of accessibility
in function of the intensity of the primer extension products
is compiled in Table 1. This analysis led to the identiﬁcation
of 10 potential sites, located from positions 276 to 885, of
the APP transcript. Seven of these sites appeared to be highly
accessible, including 5 that were located near position 450. A
high concentration of such sites in the same area is indicative
ofasingle-strandedregion,althoughitmayalsoresultfroma
synergetic eﬀect of several oligonucleotides binding the same
RNA transcript, resulting in unfolding of that region and
increasingthepossibilitythatadditionaloligonucleotidescan
also bind.
Subsequently, HDV-Rz with the appropriate recognition
sequences was designed. To increase speciﬁcity, the ribozyme
was further extended with the addition of a SOFA module.
The resulting ribozymes were named SOFA-HDV-Rz-APPX,
where X represents the APP cleavage position. The ability of
these ribozymes to cleave the 5 -end-labeled APP transcripts
was tested under single-turnover conditions ([Rz]   [S])
a n da n a l y z e dv i aP A G E( Figure 2 inset). Clearly, all of the
SOFA-HDV ribozymes exhibited cleavage activity, although
at diﬀerent levels. Speciﬁcally, the cleavage level varied from
4% to 71%. Moreover, all of the ribozymes exhibited a spe-
ciﬁc cleavage at only the expected site. The 4 SOFA-HDV
ribozymes that exhibited a cleavage level higher than 30%
were conserved for the subsequent step. These ribozymes
included SOFA-HDV-Rz-APP276, -APP753, -APP756, and
-APP885, with cleavage activities of 62%, 36%, 36%, and
71%, respectively. These 4 potential SOFA-HDV ribozymes
targeting the APP mRNA were tested with the ribosubstrates
online software (http://www.riboclub.org/ribosubstrates).
This integrated software searches selected cDNA databases
for all of the potential substrates for a given SOFA-HDV
ribozyme [18]. These potential substrates include not only
mRNAs with perfect matches with the catalytic RNA tested,
but also the wobble bp and mismatches. Interestingly,
none of these 4 potential SOFA-HDV ribozymes seemed to
have the potential for oﬀ-target eﬀects (data not shown).
Moreover,thisanalysisindicatedthatnoothercleavagecould
occur within the APP gene family. Therefore, the chosen
sequences were speciﬁc to APP mRNA. In other words, the
SOFA-HDV ribozymes that exhibited signiﬁcant cleavage
activity in vitro against a derived APP transcript appeared to
be speciﬁc to the APP mRNA.
3.2. Expression of APP-Speciﬁc SOFA-HDV Rz in Human
Cells. In an attempt to achieve a high level of expression of
SOFA-HDV ribozymes that maintain their aﬃnity for the
targeted mRNA, we adopted the pRNAT/U6 (which employs
the U6 RNA polymerase III promoter) for a high level of
small RNA expression. The advantage of this promoter is
that RNA transcription terminates with the addition of 4
or 5 uridines (U) at the 3 -end, and this change has only
a minimal eﬀect on SOFA-HDV ribozyme folding based
on RNA structure predictions. This approach also avoids
nonspeciﬁc eﬀects that might be caused by the transcription
of additional regions of the vector sequence.
To determine whether the pRNAT/U6 SOFA-HDV-Rz-
APPX vector could express the anti-APP SOFA-HDV ribo-
zymes, these constructs were transfected into HEK-293 cells.
Two days after transfection, total RNA from transfected cells
was subjected to primer extension analysis. EndogenouslyInternational Journal of Alzheimer’s Disease 7
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Figure 3: Expression of APP-SOFA-HDV ribozymes in the HEK
cell line. Primer extension analysis of total cellular RNA from cells
transfected with four selected APP-SOFA-HDV ribozymes from the
ribozyme collection (APP-SOFA-HDV-Rz276, APP-SOFA-HDV-
Rz753, APP-SOFA-HDV-Rz756, and APP-SOFA-HDV-Rz885).
Transcripts corresponding to HDV-ribozymes were detected with
HDV-Rz primers (5 -GGGTCCCTTAGCCATGCGCGAACG-3 ).
U6 primer (5 -GGCCATGCTAATCTTCTCTG-3 ) was also used as
a positive control, which yielded signals corresponding to endo-
genous U6 snRNA. Note that all of the 4 selected SOFA-HDV ri-
b o z y m e sw e r ee x p r e s s e d( l a n e s1t o4 ) .Ap R N A Te m p t yv e c t o r ,w a s
used as a negative control.
synthesized U6 snRNA and SOFA-HDV ribozymes tran-
scribed from the U6 promoter were detected, respectively, by
U6-andDrz 32P-labeledprimers(seeSection 2).Asindicated
by Figure 3 (lanes 1 to 8), the speciﬁc extension products
corresponding to U6 SOFA-HDV-Rz-APP276, -APP753, -
APP756, and -APP885 were detectable in the transfected
cells. An expression vector lacking a SOFA-HDV ribozyme
codingsequence(pRNAT/U6)wasusedasanegativecontrol.
No detectable band of Drz 32P-labeled primers was observed
with the empty vector (Figure 3, lane 9). The expression
levels for SOFA-HDV-Rz-APP753 and -APP885 were among
the highest, while two other ribozymes (SOFA-HDV-Rz-
APP276, and -APP756) exhibited weaker expression.
3.3. Eﬀect of Selected SOFA-HDV Ribozymes on APP mRNA
Expression Level. Considering the close and positive cor-
relation between the level of APP mRNA, protein, and
Aβ deposition in AD [19], APP mRNA expression levels
following APP SOFA-HDV ribozyme expression were ini-
tially monitored. Previously, it has been shown that the
SOFA-HDV Rz expressed in HEK-293 cells could be a
powerful and speciﬁc gene silencing tool [9]. Therefore,
SOFA-HDV-Rz-APP was transiently transfected into HEK-
293 cells, which are well known for the expression of endo-
genous APP mRNA. pRNAT-U6 empty vector was used
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Figure 4: Relative APP mRNA level in HEK-293 cells expressing
APP-SOFA-HDV Rz. The expression proﬁle of APP in SOFA-HDV-
Rz276-, -Rz753-, -Rz756-, and -Rz885-transfected HEK-293 cells.
ToassessAPPknockdowneﬃciencyatthemRNAlevel,quantitative
real-time PCR was performed with each of the forward and reverse
APPorGAPDHprimersusingtheABIPrism7000SequenceDetec-
tion System and SYBR Green DNA binding dye (Invitrogen). The
speciﬁc ampliﬁcation was assessed based on the dissociation curve
proﬁle. The APP gene expression proﬁle was normalized against
that of GAPDH. The quantitative PCR procedure was performed
in duplicate in three independent reactions for each sample. ∗∗P<
0.01. An approximately 70–80% decrease in GAPDH-normalized
APP mRNA levels was observed with cells expressing active SOFA-
HDV Rz (the most potent Rz). The GAPDH-normalized levels of
endogenous APP were not signiﬁcantly altered in the untreated or
empty vector-transfected control cells.
as a control. The total RNA was extracted from cells 48h
after transfection, and APP mRNA levels were quantiﬁed
by real-time quantitative PCR (qPCR). The GAPDH mRNA
was used as a control for the qPCR to normalize the APP
mRNA levels. A signiﬁcant eﬀect of SOFA-HDV-Rz-APP
ribozyme expression on cellular APP mRNA levels was
observed (Figure 4). SOFA-HDV-Rz-APP276 and -APP753
transfection led to a highly signiﬁcant (P<0.001; Student’s
t-test) decrease in APP mRNA steady-state levels (∼70%
and 80%, resp., relative to the control cells). Conversely,
both SOFA-HDV-Rz-APP756 and -APP885 expression did
not show a signiﬁcant decrease at the APP mRNA level,
suggesting that cleavage sites at positions 756 and 885 may
not be as accessible in cellulo as they were in the in vitro
assays on partial mRNA transcripts. The transfection of
cells with an empty vector resulted in a faint increase in
APP mRNA compared with untransfected cells (Figure 4,
lanes 5 and 6), but this eﬀect was not signiﬁcant (P>
0.05; Student’s t-test). More importantly, this experiment
providedphysicalevidencethattheexpressionofbothSOFA-
HDV-Rz-APP276 and -APP753 in HEK-293 cells resulted
in an important decrease of the targeted APP mRNA levels
and that nonspeciﬁc eﬀects of vector transfection could not
account for this decrease.
3.4. Eﬀect of the SOFA-HDV Ribozyme on APP Protein
Levels. Because the correlation between the level of mRNA8 International Journal of Alzheimer’s Disease
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Figure 5: Rz-APP-X ribozymes expression reduces APP levels. (a)
Western blotting analysis performed using equal amounts of 20μg
of extracted protein. APP was immunodetected using a polyclonal
antibody (Sigma) recognizing the C-terminus of human APP. The
tubulin(β-tubulin)controlledtheamountofsampleloadedineach
lane.ThehighestAPPreduction(approximately85%)wasobtained
with Rz-APP-276 and Rz-APP-753. (b) Densitometric quantiﬁca-
tion of the APP lanes in the blot from (a). Relative density unit
values were obtained by standardization with the corresponding β-
tubulin protein band in each lane. The results in (b) are presented
as the means ± SEM from 3 independent experiments. ∗∗P<0.01.
and its concomitant protein is not always linear, the eﬀect
of APP’s directed SOFA-HDV ribozymes on APP protein
levels was then investigated to verify whether the decrease
in APP mRNA level results in a reduction at the protein
level. SOFA-HDV-Rz-APP ribozymes were transfected into
HEK-293 cells. As a control, cells were transfected with
a pRNAT-U6 vector expressing GFP protein. At 48h after
transfection, the cells were lysed and total proteins were
extracted. Subsequently, a Western blot was performed with
a speciﬁc anti-APP C-terminal antibody as a probe. The level
of APP was estimated by densitometry and normalized using
endogenous β-tubulin (Figure 5). As expected, cells express-
ing both SOFA-HDV-Rz-APP276 and -APP753 showed a
drastic decrease in APP levels compared with un transfected
cells, those transfected with empty vector or those trans-
fected with SOFA-HDV-Rz-APP885 (Figure 5(a)). The last
construct exhibited a decrease estimated to be less than
20%, whereas the two other ribozymes led to reductions of
over 70% relative to the controls. All of the changes were
highly signiﬁcant (P<0.001) when compared with either
untransfected cells or cells transfected with pRNAT/U6.
Thus, the decrease in APP mRNA resulting from the
expression of SOFA-HDV ribozyme is correlated with the
changeobservedattheproteinlevel.Moreover,thesedataare
strongly consistent with the hypothesis that the expression
level of APP mRNA is closely and positively correlated with
its concomitant protein level [20].
3.5. Assessment of Aβ Secretion Levels in SOFA-HDV Ribo-
zyme-Treated Cells. From the perspective of AD therapy,
any attempts to decrease APP mRNA levels should also
result in a decrease in Aβ levels. To assess whether a decline
of APP in ribozyme-treated cells leads to a decline in
total Aβ levels, the level of secreted Aβ following SOFA-
HDV-Rz-APP expression was determined by ELISA. For
this experiment, the SOFA-HDV-Rz-APP276 and SOFA-
HDV-Rz-APP753 were selected as the two more active and
powerful ribozymes. Because neurons will be the target of
the ribozymes in the context of AD, this ribozyme was tested
on a neuronal cell type, SHSY-5Y, using a lentiviral system of
expression. This system is essential for transducing neurons
becausepost-mitoticcellscannotbeeﬃcientlytransfectedby
other vectors. Following SHSY-5Y transduction, the SOFA-
HDV-Rz-APP753 expression was tested for its eﬀect on the
reduction of APP at both the mRNA and protein levels (data
not shown). To evaluate the Aβ level, media samples were
collected and analyzed for Aβ1−x species, as both Aβ40 and
Aβ42 are associated with AD pathogenesis. Knocking down
APP with lentiviral SOFA-HDV-RzAPP276 or OFA-HDV-
RzAPP753 transduction of SHSY-5Y cells reduced the total
levelofAβ bymorethan30%(Figure 6).Thisresultindicates
that a SOFA-HDV ribozyme could be a potential means of
targeting APP.
4. Discussion
In this study, we designed a new molecular tool to target
the top of the amyloid cascade, namely, the APP mRNA.
The SOFA-HDV ribozyme is based on a new synthetic
HDV ribozyme harboring a biosensor module that activates
mRNA cleavage only in the presence of the speciﬁc RNA
target substrate [9]. This speciﬁc On/Oﬀ adapter (SOFA
module)providesnotonlyahigherspeciﬁcitytotheHDVRz
toward its target but also a higher cleavage capacity [10]. An
initial experiment to identify the most susceptible site within
the 5  end region of the APP mRNA was performed based
on the use of a randomized library of short oligonucleotides
mimicking the recognition domain of the ribozyme. The
hydrolysis of the formed RNA/DNA heteroduplexes by the
RNase H led to the identiﬁcation of 10 potential sites
(Table 1). In vitro cleavage of a partial APP transcript
by the corresponding appropriate SOFA-HDV ribozymes
revealed that 4 of these sites could be cleaved at a signiﬁcant
level (Figure 2). Interestingly, an analysis of the sequence
and secondary structure of the SOFA-HDV ribozymes thatInternational Journal of Alzheimer’s Disease 9
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Figure 6: Eﬀect of the most active ribozyme on the level of
secreted total amyloid. The secreted levels of Aβ1−x were detected
by sandwich ELISA, as described in Section 2. Media were collected
following SH-SY5Y infection with the Rz-APP-286, Rz-APP-753, or
pRNATemptyvector.Theresultsarepresentedasthemeans ±SEM
from 3 independent experiments. ∗∗P<0.001. Control cells were
infected with the empty pRNAT vector.
exhibited only moderate cleavage activity indicated that
misfolding of 5 out of 6 of these ribozymes may explain
their limited potential (data not shown). Therefore, only one
of the SOFA-HDV ribozymes did not cleave eﬃciently for
any speciﬁc reason. This result is excellent, considering that
the initial analysis was based on the hybridization of small
oligonucleotidesandthattheSOFA-HDVribozymeisalmost
a magnitude larger in size but possesses a complex tertiary
structure and two binding domains that interact with the
substrate (i.e., the recognition and biosensor domains) and
undergoes conformation transition [21].
The SOFA-HDV ribozymes exhibiting the highest cleav-
age activity in vitro were further studied in cellulo. These
ribozymes were expressed from a U6 promoter for the RNA
pol III because it allows eﬃcient transcription of small
RNA molecules [22]. According to the primer extension
assays performed for these four SOFA-HDV ribozymes,
they all exhibited good expression, although variable, in
transfected HEK293 cells (Figure 3). Therefore, neither their
ability to be expressed nor their stability accounted for their
variable cleavage activity. Two of the SOFA-HDV ribozymes
exhibited equivalent and drastic reductions in APP at both
the mRNA and protein levels (Figures 4 and 5;S O F A -
HDV Rz-APP276 and -APP753). It is not surprising that
only some of the ribozymes that showed excellent cleavage
activity in vitro exhibited signiﬁcant cleavage activity in
cellulo.S e v e r a ld i ﬀerent factors in cells compared with the
in vitro analysis may account for this result. The in cellulo
target is the full-length mRNA, which may adopt a diﬀerent
structure,andcellularproteins maybebound toit andcreate
steric hindrances that reduce the accessibility to some of the
identiﬁed cleavage sites.
To our knowledge, this study is the ﬁrst reporting acute
silencing of APP in human cells using an HDV ribozyme-
based approach. SOFA-HDV ribozyme-based gene silencing
constitutes an alternative to using small interfering RNA,
a method that faces several limitations. One of the largest
hurdles in RNAi-based therapy is toxicity. In this context,
independent oﬀ-target or nonspeciﬁc eﬀects of siRNA are
ac o n c e r n[ 23, 24]. Side eﬀects can result from unintended
interactions between an siRNA compound and an unrelated
host gene. This nonspeciﬁc interaction with host genes
may cause adverse eﬀects in the host. Moreover, shRNA
expression in neurons has been shown to interfere with
dendriticspinestructureandfunction,resultinginadecrease
of synapses [25]. Interferon response is the best known
adverse eﬀect in the viral-mediated transfection of siRNAs.
Similarly, synthetic siRNAs formulated in nonviral delivery
vehicles can also be potent inducers of interferons and
inﬂammatory cytokines, both in vivo in mice and in vitro in
human blood [26]. The most important diﬀerence between
ribozyme technology and RNAi technology is that RNAi
requires the recruitment of endogenous proteins, which are
responsibleforthehighintracellularactivity.Thus,problems
of potency, speciﬁcity, and/or cell-type-dependent responses
illustrate a lack of understanding of the intracellular mecha-
nisms involved [27]. By contrast, the HDV Rz, which derives
from the hepatitis delta virus, possesses several unique
features that are all related to the fact that it is the only
naturally occurring catalytic RNA discovered in humans [7,
28, 29] and that its action does not depend on intracellular
factors [30]. In addition, it exhibits an outstanding stability
(i.e., a half-life > 100hr) in cell culture [8]. Moreover, a
genome-widesearchforinnateribozymeentitiesrevealedthe
presence of HDV-like sequences in the human CPEB3 gene
[31]. Consequently, the HDV Rz should not be recognized
by the immune system as an external, invading RNA.
Several studies in human genetic and animal models
supportthenotionthatamyloidproductionoraccumulation
in the brain plays a central role in the pathogenesis of
AD. Lowering amyloid levels in diﬀerent mouse models
has demonstrated therapeutic value [32, 33]. Multiple
approaches aimed at interfering with Aβ metabolism have
been proposed as a therapy for AD. First, compounds that
aim to decrease the aggregation of Aβ by blocking its
oligomerization have been tested [34]. Although successful
in mice models of AD, they failed in human trials. Second,
lowering Aβ levels by increasing its clearance using a vaccine
wassuccessfulinanimalmodels[35,36],buttheresultsfrom
human clinical studies indicated important side eﬀects, and
there were concerns about safety in humans [37]. Finally,
blocking the activity of the secretases (β and γ) is attractive
because both of these enzymes participate in Aβ produc-
tion by cleaving APP. However, because these secretases
have numerous substrates essential for cellular functions,
blocking their activity raises additional concerns. The data
from β-secretase (BACE1) knockout animals have suggested
potential liabilities with BACE1 inhibition [38–40]. BACE1
is also known to participate in myelination [41–43] and the
processing of sodium channels [43]. Nonetheless, BACE1
inhibitors have been developed, but blood-brain-barrier10 International Journal of Alzheimer’s Disease
penetration and limited access to cellular BACE1 due to its
major location in the endosome pose signiﬁcant challenges
that have yet to be overcome [44, 45]. Another potential
therapeutic target is γ-secretase, although it has numerous
essential cellular substrates. However, recent clinical trials
testing a very promising γ-secretase inhibitor have raised
major safety issues about this route [46, 47]. This failure
does not question the amyloid hypothesis, but instead the
nonspeciﬁc targeting of an enzyme complex with so many
cellular functions [48].
Because there have been many failures in targeting amy-
loid peptide metabolism, we believe that targeting the top
of the cascade by decreasing APP mRNA would be a
better way to decrease the overall amyloid level. We do
not expect a complete knock down of APP mRNA and
Aβ, but we are conﬁdent that we can signiﬁcantly reduce
APP mRNA levels (and subsequently, Aβ levels). We believe
that there is a threshold eﬀect and that a modest reduction
in Aβ levels could shift the balance between toxicity and
nontoxicity. Another advantage of speciﬁcally targeting APP
mRNA is that the level of all forms of the peptide derived
from APP will also be decreased. To achieve this end, we
engineered speciﬁc SOFA HDV ribozymes, a new generation
of catalytic RNA tools, to decrease the APP mRNA level.
We demonstrated that a SOFA-HDV ribozyme targeting
APP mRNA is clearly eﬀective for the reduction of Aβ in
neuron-likecells.Furtheranalysisusinganexpressionsystem
based on the lentivirus indicated a signiﬁcant decrease of
∼30% in total Aβ levels (Figure 6). Therefore, this action
couldpossiblyaﬀectdownstreamamyloid-relatedpathology.
Becauseonlya12%decreaseinAβ levelsinmiceresultedina
dramaticreductioninAβ build-upandsynapticdeﬁcits[49],
we are optimistic that the results obtained in our cellular
model will allow for the development of an eﬃcacious form
of SOFA-HDV ribozyme-based therapy. The exact role of
Aβ as a trigger of sporadic Alzheimer’s disease is still a
question of debate. Moreover it is actually not clear which
Aβ species is associated with the disease. Over production
of Aβ is probably not the cause of amyloid accumulation in
sporadic AD. A defective clearance of amyloid may trigger
its aggregation. This is supported by the fact that the ApoE4
allele, which is the major genetic risk factor for sporadic
AD, slows down Aβ clearance [50]. Whatever the cause of
Aβ accumulation, we believe that decreasing Aβ production
by speciﬁcally targeting the APP mRNA will contribute to a
decrease in the amyloid load to a non-toxic level. Actually,
all therapies targeting Aβ (secretase inhibitors, vaccines, etc.)
aim to reach this nontoxic level.
One limitation of our gene silencing approach is the
delivery of the ribozyme to the nervous system. The presence
of the blood-brain barrier limits the penetration of particle
as large as a lentivirus into the central nervous system
(CNS). To avoid this limitation local stereotaxic injections of
lentiviruses could be used. Although this method is invasive,
robust long-term and nontoxic lentiviral gene transfer is
feasibleintherodentandnonhumanprimatebrains[51,52].
Expression over 3 to 8 months can be achieved and it has
been demonstrated that up to 90% of cells from the central
nervous system transduced by a lentiviral vector under the
control of the NSE promoter are neurons [53, 54]. However
the method of choice for lentiviral delivery is the i.v. or i.p.
route.Thiscouldbeachievedbythefusionofthelow-density
lipoprotein receptor-binding domain of the apolipoprotein
B to the therapeutic molecule. Successful application of this
approach as a general method for the delivery of therapeutic
moleculestotheCNShasbeendemonstrated[55].Moreover
it remains possible that systemic presence of SOFA HDV
ribozymes will decrease Aβ level in the periphery and
concomitantly brain Aβ levels due to the “sink hypothesis.”
Evaluation of these delivery methods will involve extending
our study to animal models of Alzheimer’s disease, thus the
exciting potential of this new treatment will be revealed in
the future.
This development will involve extending our study
to animal models of Alzheimer’s disease, so the exciting
potential of this new treatment will be revealed in the future.
Wehavepresentedanoriginalandunambiguousdemon-
stration that a SOFA-HDV ribozyme can serve as an eﬃcient
gene silencing tool. Moreover, our results open the door
to further evaluation of SOFA-HDV ribozymes as potential
therapeutic molecules, or at least to a study demonstrating
w h e t h e rar e d u c t i o ni nA β levels is a viable therapy against
Alzheimer’s disease.
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